Advances in radiological imaging studies have simplified the diagnosis of Budd-Chiari syndrome (BCS), but many challenges still remain with respect to therapy. Patients with BCS who have a hematological disorder are an especially difficult group to treat. Major issues related to the treatment of BCS
The budd-chiari syndrome in a patient with hepatic gummata
β Scribed by P. W. Dykes; H. A. Ellis; A. Gourevitch
- Publisher
- John Wiley and Sons
- Year
- 1963
- Tongue
- English
- Weight
- 548 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0007-1323
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Budd-Chiari syndrome (BCS) is the end result of a number of disease states resulting in hepatic venous outflow obstruction. We report a Janus kinase 2-homozygous patient with BCS who thrombosed a transjugular intrahepatic portosystemic shunt (TIPS) despite treatment with warfarin (international norm
The long-term results of liver transplantation for Budd-Chiari syndrome (BCS) and timely indication for the procedure are still under debate. Innovations in interventional therapy and better understanding of underlying diseases have improved therapy strategies. The aim of this study was the analysis
Budd-Chiari syndrome (BCS) is a rare disorder that is characterized by hepatic venous outflow obstruction. The aim of this study was to assess determinants of survival and to evaluate the effect of portosystemic shunting. In this international multicenter study, 237 patients with BCS, diagnosed betw
Budd-Chiari syndrome is characterized by hepatic venous outflow obstruction. Although myeloproliferative disorders are usually responsible for this severe thrombotic disorder, deficiency or dysfunction of the natural anticoagulants can be involved. Resistance to activated protein C caused by factor